ChinaBio® Today Blog | Talkmarkets | Page 1
News and insights into the #2 pharma/medtech market - China

Greg B. Scott founded ChinaBio® in 2007 to help western life science companies achieve success in China. ChinaBio® is a consulting and advisory firm based in Shanghai that has helped over 100 U.S., European and APAC companies seeking partnerships, acquisitions, novel ... more

Articles

Latest Posts
1 to 16 of 387 Posts
1 2 3 ... 25
Week In Review: Hansoh In-licenses Endometriosis/Fibroid Therapy In $170 Million Deal
Other funding deals for drug discovery, R&D, gene editing.
Week In Review: Innovent Lands $305 Million Investment From Sanofi; Will Partner Two Candidates In China
Suzhou Innovent Biologics will develop two Sanofi cancer candidates for China use in a complicated deal with money due to each company. Sanofi will initially invest $305 million in Innovent shares.
Week In Review: China Biopharma Tops $2.8 Billion In Week's Dealmaking
CSPC Pharma out-licensed global rights for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. CSPC will receive a $27 million upfront payment and up to $148 million in development and regulatory milestones.
Week In Review: WuXi Biologics And WuXi AppTec Plan $2.8 Billion Investment In Singapore Facilities
WuXi Biologics and WuXi AppTec announced that each company would invest $1.4 billion over ten years to build R&D and manufacturing facilities in Singapore. Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs.
Week In Review: Qiming Closes $3.2 Billion For China Healthcare And Technology Investments
Qiming Venture Partners closed two new China healthcare and technology funds with $3.2 billion in fresh capital, both of them at their hard cap limits. The USD Fund VIII has $2.5 billion and the first round of RMB Fund VII closed at RMB 4.7 billion.
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make investments in China’s healthcare and tech companies.
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones.
Week In Review: InvoX, A Sino Biopharma Company, To Pay $161 Million To Acquire F-Star
InvoX Pharma, a Sino Biopharma subsidiary, will pay $161 million to acquire F-Star, a clinical stage company developing bispecific drugs for immunotherapies. Meanwhile, Reistone Biopharma completed a Series A financing of nearly $100 million.
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global expansion.
Week In Review: Fosun Pays $158 Million For Controlling Stake In Singapore Medical Centers
Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. Oncocare is one of Singapore’s largest private medical oncology specialist centers.
Week In Review: Vivo Raises $600 Million In First Tranche Of China PE Fund
Vivo Capital held its first closing of a yuan-denominated private equity fund at $600 million, with a target of bringing the fund to $1.5 billion. Meanwhile, ProfoundBio closed a $70 million Series A+ financing round led by Sequoia China.
Week In Review: Fosun Acquires VerImmune Cancer Immunotherapy In $125 Million Deal
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in an $125 million agreement. Fosun will pay VerImmune up to $125 million in upfront and milestone payments, plus tiered royalties.
Week In Review: Hengrui Launches US Subsidiary To Bring Novel Medicines To Global Markets
Hengrui Pharma launched a new company, Luzsana Biotechnology, which is devoted to making the most advanced medications available and affordable. Meanwhile, Sichuan Kelun Pharmaceutical out-licensed global rights for a molecule candidate to Merck.
Week In Review: Zhaoke Signs $130 Million Deal For Vision-Improving Eyedrops
Zhaoke Ophthalmology acquired China/Southeast Asia rights for two eyedrop candidates from Visus Therapeutics in a $130 million deal. Meanwhile, Coherus Biosciences returned the US rights to market an Innovent Avastin biosimilar.
Week In Review: OrbiMed Plans To Raise $1.1 Billion For Fifth Asia Fund
One year after raising $3.5 billion for three funds in 2021, OrbiMed, the world’s largest healthcare-dedicated investor, is back with plans for $4.75 billion in new funds despite the slowdown in biopharma exits over the past year.
Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company
I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings total funds raised since inception to $140 million.
1 to 16 of 387 Posts
1 2 3 ... 25